Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market - Research and Markets

Research and Markets
Posted on: 14 Aug 17

The "Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market" report has been added to Research and Markets' offering.

China has the most newly diagnosed CRC cases in Asia-Pacific (APAC). In 2011, there were 310,200 incident cases in the country and this rose to 376,300 in 2015. CRC is the most common malignancy among Chinese males, with an estimated incidence of 215,700 men and 160,600 women in 2015. Mortality in 2011 stood at 149,700, and in 2015 rose to 191,000.

In Japan, the incidence and mortality of CRC have substantially increased. In 2012, the incidence of colon and rectum cancer in Japan was 87,800 and 46,800 cases respectively, and mortality was 32,200 and 15,100 cases. CRC is a major cause of death in Japan, where it accounts for the largest number of deaths from malignant neoplasms among women, and the third largest among men. In 2016, there were an estimated 147,200 new CRC cases and 51,600 deaths in the country.

In Australia, the five-year survival rate increased from 50% between 1984 and 1988 to 69% between 2009 and 2013. Improvement in survival from CRC may be due to earlier diagnosis and the availability of better treatment options. The incidence of CRC is still several folds lower in India than in most developing and developed countries. However, the country has witnessed a steady increase in numbers in line with its increasing urbanization.

Companies Mentioned

  • AB Science
  • Amgen
  • Array BioPharma
  • Bayer
  • Eli Lilly
  • Hutchison MediPharma
  • Jiangsu Chia-Tai Tianqing
  • Merck & Co.
  • Onyx
  • Regeneron
  • Roche
  • Sanofi
  • Sumitomo Dainippon Pharma
  • Suzhou Zelgen Biopharmaceuticals
  • Taiho Pharma
  • Takeda

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Marketed Products

4 Pipeline Analysis

5 Clinical Trial Analysis

6 Multi-scenario Forecast

7 Drivers and Barriers

8 Deals and Strategic Consolidations

For more information about this report visit

View source version on

Business Wire

Last updated on: 14/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.